期刊文献+

CYP3A4和P糖蛋白与药物的肠道处置 被引量:3

Impact of CYP3A4 and P-glycoprotein on drug disposition in intestine
下载PDF
导出
摘要 肠CYP3A4介导的生物转化和P糖蛋白介导的药物主动泵出肠细胞是决定口服药物生物利用度的主要因素。有证据显示CYP3A4和P糖蛋白在小肠不是共同调节的,但两者在药物肠道处置中的协同作用已得到体外试验和动物体内试验的证实。进一步了解两者的相互作用有助于改善CYP3A4/P糖蛋白底物的生物利用度。 Intestinal CYP3A4-mediated biotransformation and active efflux of absorbed drug by P-glycoprotein are major determinants of bioavailability of orally administered drugs. The expression of CYP3A4 and P-glycoprotein in the intestine is not co-ordinately regulated. However, synergistic actions of CYP3A4 and P-glycoprotein in intestinal drug disposition have been confirmed by in vitro and animal studies. Further understanding of this interaction would be potentially useful to improve oral bioavailability of CYP3A4/P-glycoprotein substrates.
作者 辛华雯
出处 《中国临床药理学与治疗学》 CAS CSCD 2005年第7期721-725,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 湖北省自然科学基金资助课题(№2002AB114)
关键词 CYP3A4 P糖蛋白 药物代谢 肠道 肝脏首过代谢 生物利用度 相互作用 CYP3A4 P-glycoprotein drug metabolism intestine liver first-pass metabolism bioavailability drug interaction
  • 相关文献

参考文献35

  • 1Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, et al. Molecular and physical mechanisms of first-pass extraction[J]. Drug Metab Dispos, 1999;27:161 - 6
  • 2Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa[J]. Gastroenterology, 1992; 102:879-85
  • 3Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans[J]. Adv Drug Deliv Rev, 2002;54:1295- 310
  • 4Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance[J]. Clin Pharmacol Ther, 2004;75:13 - 33
  • 5Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery[J]. J Control Release, 1999; 62:25- 31
  • 6von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M,Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens[J]. Clin Pharmacol Ther, 2004;75:172-83
  • 7Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine [J]. Clin Pharmacol Ther, 1995;58:492 - 7
  • 8Lown KS, Bailey DG, Fontana R J, Janardan SK, Adair CH,Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression[J]. J Clin Invest, 1997;99:2545 - 53
  • 9Thummel KE, O' Shea D, Paine MF, Shen DD, Kunze KL,Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism[J]. Clin Pharmacol Ther, 1996;59:491 - 502
  • 10von Richter O, Greiner B, Fromm MF, Fraser R, Omari T,Barclay ML, et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique [ J ]. Clin Pharmacol Ther, 2001 ;70:217 - 27

同被引文献48

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部